Io­n­is launch­es an ear­ly-stage tau drug study for Alzheimer’s, pick­ing up $10M from Bio­gen

Af­ter amy­loid be­ta, the sec­ond big tar­get in Alzheimer’s dis­ease cen­ters on tox­ic ac­cu­mu­la­tions of tau, pos­si­bly work­ing hand-in-hand with a-be­ta to fry peo­ple’s mem­o­ries. And to­day Io­n­is $IONS says that it’s pick­ing up a $10 mil­lion mile­stone from its part­ners at Bio­gen to be­gin an ear­ly-stage study that will set out to try and de­ter­mine if its an­ti­sense tech can make a dif­fer­ence in dis­ease pro­gres­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.